The strategic deployment of Gr-1-targeting neutralizing antibodies or the potent antitumor agent gemcitabine effectively contained the overall MDSC population, countered the decrease in the infiltration of both CD4+ and CD8+ T cells, and alleviated the phenotype of expedited tumor growth evident in LLC cells with CUL4B knockdown. Here, CUL4B is linked to neoplasm.